89 related articles for article (PubMed ID: 19893451)
21. Evidence that one subset of anaplastic thyroid carcinomas are derived from papillary carcinomas due to BRAF and p53 mutations.
Quiros RM; Ding HG; Gattuso P; Prinz RA; Xu X
Cancer; 2005 Jun; 103(11):2261-8. PubMed ID: 15880523
[TBL] [Abstract][Full Text] [Related]
22. TRAIL receptor upregulation and the implication of KRAS/BRAF mutations in human colon cancer tumors.
Oikonomou E; Kosmidou V; Katseli A; Kothonidis K; Mourtzoukou D; Kontogeorgos G; Andera L; Zografos G; Pintzas A
Int J Cancer; 2009 Nov; 125(9):2127-35. PubMed ID: 19637313
[TBL] [Abstract][Full Text] [Related]
23. Open pipelines for integrated tumor genome profiles reveal differences between pancreatic cancer tumors and cell lines.
Goecks J; El-Rayes BF; Maithel SK; Khoury HJ; Taylor J; Rossi MR
Cancer Med; 2015 Mar; 4(3):392-403. PubMed ID: 25594743
[TBL] [Abstract][Full Text] [Related]
24. Kinome Array Profiling of Patient-Derived Pancreatic Ductal Adenocarcinoma Identifies Differentially Active Protein Tyrosine Kinases.
Creeden JF; Alganem K; Imami AS; Brunicardi FC; Liu SH; Shukla R; Tomar T; Naji F; McCullumsmith RE
Int J Mol Sci; 2020 Nov; 21(22):. PubMed ID: 33213062
[TBL] [Abstract][Full Text] [Related]
25. Emerging Kinase Therapeutic Targets in Pancreatic Ductal Adenocarcinoma and Pancreatic Cancer Desmoplasia.
Creeden JF; Alganem K; Imami AS; Henkel ND; Brunicardi FC; Liu SH; Shukla R; Tomar T; Naji F; McCullumsmith RE
Int J Mol Sci; 2020 Nov; 21(22):. PubMed ID: 33233470
[TBL] [Abstract][Full Text] [Related]
26. Pharmacogenomics update in pancreatic cancer.
Puri A; Saif MW
JOP; 2014 Mar; 15(2):114-7. PubMed ID: 24618431
[TBL] [Abstract][Full Text] [Related]
27. Whole Genome Sequencing of Newly Established Pancreatic Cancer Lines Identifies Novel Somatic Mutation (c.2587G>A) in Axon Guidance Receptor Plexin A1 as Enhancer of Proliferation and Invasion.
Sorber R; Teper Y; Abisoye-Ogunniyan A; Waterfall JJ; Davis S; Killian JK; Pineda M; Ray S; McCord MR; Pflicke H; Burkett SS; Meltzer PS; Rudloff U
PLoS One; 2016; 11(3):e0149833. PubMed ID: 26962861
[TBL] [Abstract][Full Text] [Related]
28. No mutations in the tyrosine kinases of human hepatic, pancreatic, and gastric cancer cell lines.
Shao RX; Otsuka M; Kato N; Chang JH; Muroyama R; Taniguchi H; Moriyama M; Wang Y; Kawabe T; Omata M
J Gastroenterol; 2005 Sep; 40(9):918. PubMed ID: 16211354
[No Abstract] [Full Text] [Related]
29. Genome-wide characterization of pancreatic adenocarcinoma patients using next generation sequencing.
Liang WS; Craig DW; Carpten J; Borad MJ; Demeure MJ; Weiss GJ; Izatt T; Sinari S; Christoforides A; Aldrich J; Kurdoglu A; Barrett M; Phillips L; Benson H; Tembe W; Braggio E; Kiefer JA; Legendre C; Posner R; Hostetter GH; Baker A; Egan JB; Han H; Lake D; Stites EC; Ramanathan RK; Fonseca R; Stewart AK; Von Hoff D
PLoS One; 2012; 7(10):e43192. PubMed ID: 23071490
[TBL] [Abstract][Full Text] [Related]
30. Src family of tyrosine kinases: a role of c-yes in colon carcinogenesis?
Boardman LA; Karnes WE
Gastroenterology; 1995 Jan; 108(1):291-4. PubMed ID: 7806054
[No Abstract] [Full Text] [Related]
31. Copy number alterations in pancreatic cancer identify recurrent PAK4 amplification.
Chen S; Auletta T; Dovirak O; Hutter C; Kuntz K; El-ftesi S; Kendall J; Han H; Von Hoff DD; Ashfaq R; Maitra A; Iacobuzio-Donahue CA; Hruban RH; Lucito R
Cancer Biol Ther; 2008 Nov; 7(11):1793-802. PubMed ID: 18836286
[TBL] [Abstract][Full Text] [Related]
32. Efficient targeted resequencing of human germline and cancer genomes by oligonucleotide-selective sequencing.
Myllykangas S; Buenrostro JD; Natsoulis G; Bell JM; Ji HP
Nat Biotechnol; 2011 Oct; 29(11):1024-7. PubMed ID: 22020387
[TBL] [Abstract][Full Text] [Related]
33. Resequencing analysis of the candidate tyrosine kinase and RAS pathway gene families in multiple myeloma.
Hucthagowder V; Meyer R; Mullins C; Nagarajan R; DiPersio JF; Vij R; Tomasson MH; Kulkarni S
Cancer Genet; 2012 Sep; 205(9):474-8. PubMed ID: 22939401
[TBL] [Abstract][Full Text] [Related]
34. AKT1 (E17K) mutation in pancreatic cancer.
Mohamedali A; Lea NC; Feakins RM; Raj K; Mufti GJ; Kocher HM
Technol Cancer Res Treat; 2008 Oct; 7(5):407-8. PubMed ID: 18783292
[TBL] [Abstract][Full Text] [Related]
35. Emerging Roles of YES1 in Cancer: The Putative Target in Drug Resistance.
Kook E; Chun KS; Kim DH
Int J Mol Sci; 2024 Jan; 25(3):. PubMed ID: 38338729
[TBL] [Abstract][Full Text] [Related]
36. The yes-related cellular gene lyn encodes a possible tyrosine kinase similar to p56lck.
Yamanashi Y; Fukushige S; Semba K; Sukegawa J; Miyajima N; Matsubara K; Yamamoto T; Toyoshima K
Mol Cell Biol; 1987 Jan; 7(1):237-43. PubMed ID: 3561390
[TBL] [Abstract][Full Text] [Related]
37. Analysis of the genome to personalize therapy for melanoma.
Davies MA; Samuels Y
Oncogene; 2010 Oct; 29(41):5545-55. PubMed ID: 20697348
[TBL] [Abstract][Full Text] [Related]
38. [Interaction between normal and transformed epithelial cells].
Kajita M; Fujita Y
Seikagaku; 2009 Apr; 81(4):267-76. PubMed ID: 19462833
[No Abstract] [Full Text] [Related]
39. Basic principles and technologies for deciphering the genetic map of cancer.
Voidonikolas G; Kreml SS; Chen C; Fisher WE; Brunicardi FC; Gibbs RA; Gingras MC
World J Surg; 2009 Apr; 33(4):615-29. PubMed ID: 19115029
[TBL] [Abstract][Full Text] [Related]
40. YES1 Is a Targetable Oncogene in Cancers Harboring
Hamanaka N; Nakanishi Y; Mizuno T; Horiguchi-Takei K; Akiyama N; Tanimura H; Hasegawa M; Satoh Y; Tachibana Y; Fujii T; Sakata K; Ogasawara K; Ebiike H; Koyano H; Sato H; Ishii N; Mio T
Cancer Res; 2019 Nov; 79(22):5734-5745. PubMed ID: 31391186
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
